GRABAR LAW OFFICE INVESTIGATES POTENTIAL SHAREHOLDER DERIVATIVE ACTION ON BEHALF OF SHAREHOLDERS OF RECKITT BENCKISER GROUP PLC (LSE: RB.)
The investigation focuses on whether the Company’s Board of Directors and/or officers breached their fiduciary duties.
On July 11, 2019, the United States Department of Justice announced that it obtained $1.4 Billion from Reckitt Benckiser Group in “the largest recovery in a case concerning an opioid drug in United States History.” Benckiser Group plc (RB Group) agreed to pay $1.4 billion to resolve its potential criminal and civil liability related to a federal investigation of the marketing of the opioid addiction treatment drug Suboxone. The resolution included the forfeiture of proceeds totaling $647 million, civil settlements with the federal government and the states totaling $700 million, and an administrative resolution with the Federal Trade Commission for $50 million.
The Board’s failures caused the Company great financial and reputational harm. Viable claims may exist against Reckitt Benckiser’s Board for breaches of their fiduciary duties and violations of federal securities laws.
Current long-term Reckitt Benckiser shareholders have standing to seek corporate governance reforms, the return of funds from Director and Officer liability policies back to company coffers, and a court approved shareholder incentive award if appropriate.
If you would like to learn more at no cost to you, fill out the form provided or contact us at jgrabar@grabarlaw.com.
ATTORNEY ADVERTISING DISCLAIMER: These materials have been prepared by the Grabar Law Office for informational purposes only and does not constitute legal advice. This information is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Online readers should not act upon this information without seeking professional counsel. Prior results referred to in these materials do not guarantee or suggest a similar result in other matters.